Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE).
[1] It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases.
[2] In 2021, telitacicept was approved in China for the treatment of patients with active SLE.
[3] It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS).
[3] Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).